Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease.
- DOI
- 10.1016/j.repc.2019.02.008
- Published
- 2019 Oct
- Container
- Revista portuguesa de cardiologia
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.repc.2019.02.008,
title = {Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease.},
author = {Monteiro P and Aguiar C and Matos P and Silva-Nunes J and Birne R and Branco P and Calado J and Melo M and Polónia J},
year = {2019},
journal = {Revista portuguesa de cardiologia},
doi = {10.1016/j.repc.2019.02.008},
url = {https://doi.org/10.1016/j.repc.2019.02.008}
}RIS
TY - JOUR TI - Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. AU - Monteiro P AU - Aguiar C AU - Matos P AU - Silva-Nunes J AU - Birne R AU - Branco P AU - Calado J AU - Melo M AU - Polónia J PY - 2019 JO - Revista portuguesa de cardiologia DO - 10.1016/j.repc.2019.02.008 UR - https://doi.org/10.1016/j.repc.2019.02.008 ER -
APA
P, M., C, A., P, M., J, S., R, B., P, B., J, C., M, M., & J, P. (2019). Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease.. Revista portuguesa de cardiologia. https://doi.org/10.1016/j.repc.2019.02.008
Source records
- pubmed · retrieved 2026-09-27T10:56:28.754Z